arrow
H

Hermine I. Brunner

department of pediatrics
H指数:67
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcome measures in paediatric rheumatology: the contribution of the Paediatric Rheumatology INternational Trials Organisation and the Pediatric Rheumatology Collaborative Study Group

儿科风湿病学中的结局指标:儿科风湿病学国际试验组织(PRINTO)和儿科风湿病学协作研究组(PRCSG)的贡献

2026-09-090
OA
Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label study

certolizumab pegol在活动性幼年特发性关节炎患儿和青少年中的药代动力学、有效性和安全性:一项多中心、开放标签研究的9年以上结果

2026-07-280
PRE
Cognitive Behavioral Therapy for Youth With Childhood-Onset Lupus: A Randomized Clinical Trial

儿童期发病狼疮患儿的认知行为疗法:一项随机临床试验

2026-03-010
OAAI
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial

系统性红斑狼疮儿科患者皮下注射贝利木单抗的药代动力学、药效学和安全性:一项多中心、开放标签试验

2026-02-011
OAAI
Validation of the Pediatric Arthritis Ultrasound Scoring System for the Elbow, Wrist, and Finger Joints in Children With Juvenile Idiopathic Arthritis

儿童特发性关节炎患儿肘、腕、指关节的儿科关节炎超声评分系统验证

2026-02-010
OAAI
2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus

2025年美国风湿病学会(ACR)系统性红斑狼疮治疗指南

2025-11-040
PRE
2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus

2025年美国风湿病学会(ACR)系统性红斑狼疮治疗指南

2025-11-030
PRE
Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase III, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial

托法替布治疗幼年特发性关节炎:一项III期、随机、双盲、安慰剂对照撤药试验中的患者报告结局

2025-10-310
OAAI
The Renal Activity Index for Lupus Identifies Active Renal Disease and Treatment Response in Adult Patients With Systemic Lupus Erythematosus and Lupus Nephritis

系统性红斑狼疮和狼疮肾炎成人患者的肾活动指数可识别活动性肾疾病及治疗反应

2025-10-270
PRE
Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial

合并使用甲氨蝶呤及既往生物制剂改善抗风湿药物暴露对托法替尼在多关节型幼年特发性关节炎患者中疗效和安全性的影响:一项III期随机撤药试验的事后分析

2025-10-070
OAAI
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study (vol 51, pg 1125, 2024)

静脉注射戈利木单抗在多关节型幼年特发性关节炎患儿中的应用:一项开放标签III期研究的长期扩展(卷51,页1125,2024)

2025-10-010
OAAI
2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis

2024年美国风湿病学会(ACR)关于狼疮肾炎筛查、治疗和管理的指南

2025-05-070
PRE
Comparative Effectiveness and Safety of the JAK Inhibitors and Biologic Disease-Modifying Antirheumatic Drugs in Treating Children With Nonsystemic Juvenile Idiopathic Arthritis: A Bayesian Meta-Analysis of Randomized Controlled Trials

比较JAK抑制剂与生物制剂改善病情抗风湿药在治疗非系统性幼年特发性关节炎儿童中的有效性与安全性:一项随机对照试验的贝叶斯Meta分析

2025-02-180
OAAI